文献速递自身免疫性与大疱性皮肤病

14例BP180 NC16A域IgG自身抗体阴性的类天疱疮患者的临床与免疫学特征

Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
PubMed 文献 · JAMA Dermatol · 2018-01-01

该回顾性病例系列纳入2007至2016年日本久留米大学医院诊断并随访的152例类天疱疮患者,其中14例(9.2%)BP180 NC16A ELISA和/或CLEIA阴性,这些患者多无红斑、表型较轻,部分无需口服泼尼松龙,随访显示该阴性结果出现于疾病后期。

要点

  • 152例类天疱疮患者中14例(9.2%)BP180 NC16A ELISA和/或CLEIA阴性。
  • 阴性患者多数无红斑、表型相对较轻,5例(36%)无需口服泼尼松龙。
  • 14例中10例(71%)对120-kD BP180片段(LAD-1)呈阳性反应。

核心结论

  • BP180 NC16A ELISA和/或CLEIA阴性的类天疱疮患者表型较轻、红斑较少、所需治疗强度较低。

研究设计与样本

  • 回顾性病例系列研究,纳入2007至2016年在日本久留米大学医院诊断并随访的152例类天疱疮患者,诊断依据临床、组织学和免疫学表现。

主要发现

  • 152例中男69例(45.4%)、女83例(54.6%),平均(SD)年龄75.2(14.4)岁。
  • 14例(9.2%)BP180 NC16A ELISA和/或CLEIA阴性,其中2例(14%)表皮提取物完整BP180阳性,10例(71%)120-kD BP180片段(LAD-1)阳性,3例(21%)BP180 C端域阳性。
  • 7例(50%)BP230 ELISA阳性;5例(36%)无需口服泼尼松龙,其余所需泼尼松龙剂量低于30 mg/日。
  • 3例(21%)在发病前使用二肽基肽酶-4抑制剂(DPP4i),该比例与BP180 NC16A ELISA和/或CLEIA阳性患者中的19/138例(14%)相比无显著升高。
  • 随访平均(SD)31.9(33.2)周(范围0-108周),显示BP180 NC16A ELISA和/或CLEIA阴性出现在疾病后期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Enzyme-linked immunosorbent assay (ELISA) and/or chemiluminescent enzyme immunoassay (CLEIA) for BP180 noncollagenous 16A (NC16A) extracellular domain is a sensitive diagnostic tool for bullous pemphigoid (BP). However, some patients with BP have negative results for these assays. OBJECTIVE: To elucidate the clinical and immunological features of patients with BP without antibodies that react to BP180 NC16A. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series study included 152 patients who were diagnosed with BP and followed up at the Kurume University Hospital in Japan from 2007 to 2016. The diagnosis was made using clinical, histological, and immunological findings. MAIN OUTCOMES AND MEASURES: Clinical and immunological features of patients with BP who had negative results for BP180 NC16A using ELISA and/or CLEIA. RESULTS: Of the 152 patients, 69 (45.4%) were men and 83 (54.6%) were women. The mean (SD) age of participants was 75.2 (14.4) years. Of the 152 patients with BP, 14 (9.2%) had negative results for BP180 NC16A on ELISA and/or CLEIA; most of these patients exhibited no erythema and had relatively mild phenotypes. Two (14%) of the 14 patients had positive results for intact BP180 in epidermal extracts, 10 (71%) had positive results for a 120-kD fragment of BP180 (LAD-1) and 3 (21%) had positive results for BP180 C-terminal domain. Seven (50%) patients tested positive in BP230 ELISA. Five (36%) patients did not require oral prednisolone treatment, whereas the others required a dose of prednisolone at less than 30 mg per day. Three (21%) patients were administered a dipeptidyl peptidase-4 inhibitor (DPP4i) before disease onset. This ratio was not significantly higher than that in patients with BP who tested positive for BP180 NC16A ELISA and/or CLEIA (19 [14%] of 138 patients). Our follow-up study (mean [SD], 31.9 [33.2] weeks; range, 0-108 weeks) revealed that patients with BP tested negative for BP180 NC16A ELISA and/or CLEIA during the later stages of the disease. CONCLUSIONS AND RELEVANCE: This study indicates that patients with BP negative for BP180 NC16A ELISA and/or CLEIA had milder phenotypes, fewer erythemas, and required less extensive treatments.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Nakama K, Koga H, Ishii N, et al. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain. JAMA Dermatol. 2018. PMID: 29299596. doi:10.1001/jamadermatol.2017.5465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。